ArticleInternational journal of cancer2012
Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.
Article in International journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 120 citations in OpenAlex.
- TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment.Cancer immunology research · 2025Review
- Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model.International journal of molecular sciences · 2024Article
- Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects.Medical oncology (Northwood, London, England) · 2023Review
- Immunotherapies targeting tumor vasculature: challenges and opportunities.Frontiers in immunology · 2023Review
- Review
- Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling.Oncoimmunology · 2022Article
- Overcoming physical stromal barriers to cancer immunotherapy.Drug delivery and translational research · 2021Review
- Review
- Immune-related geneTranslational cancer research · 2021Article
- RTK Inhibitors in Melanoma: From Bench to Bedside.Cancers · 2021Review
- Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.Frontiers in immunology · 2021Article
- Insulin Resistance and Pellino-1 Mediated Decrease in the Activities of Vasodilator Signaling Contributes to Sunitinib-Induced Hypertension.Frontiers in pharmacology · 2021Article
- Sunitinib ExertsFrontiers in immunology · 2021Article
- NHS-IL12, a Tumor-Targeting Immunocytokine.ImmunoTargets and therapy · 2021Review
- Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?Frontiers in endocrinology · 2021Review
- Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer.Journal for immunotherapy of cancer · 2020Review
- Review
- Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.Acta pharmacologica Sinica · 2020Review
- A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.Frontiers in immunology · 2020Review
- A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.Frontiers in endocrinology · 2020Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Our study investigated the immunomodulatory effects of sunitinib to rationally design combinational platforms with immunotherapies for the treatment of solid tumors. Using a mouse model, we studied the effects of sunitinib given for 4 weeks at concentrations comparable to 37.5-50 mg/day in humans, followed by 2 weeks off the drug (sunitinib 4/2). We assessed the effect of differently timed combinations of sunitinib and a poxvirus-based vaccine encoding carcinoembryonic antigen (CEA) plus 3 costimulatory molecules on immune responses in CEA-transgenic (CEA-Tg) mice. Antitumor studies were performed in CEA-Tg mice bearing CEA-transfected MC38 murine colon carcinomas (MC38-CEA), treated either concurrently or sequentially with sunitinib and vaccine. In vitro, sunitinib inhibited PDGFR phosphorylation on MC38-CEA cells at concentrations similar to those biologically available during human treatment. In vivo, one cycle of sunitinib 4/2 caused bimodal immune effects: (a) decreased regulatory cells during the 4 weeks of treatment and (b) an immune-suppression rebound during the 2 weeks of treatment interruption. In a model using CEA-Tg mice bearing CEA(+) tumors, continuous sunitinib followed by vaccine increased intratumoral infiltration of antigen-specific T lymphocytes, decreased immunosuppressant T regulatory cells and myeloid-derived suppressor cells, reduced tumor volumes and increased survival. The immunomodulatory activity of continuous sunitinib administration can create a more immune-permissive environment. In combination with immunotherapies, sunitinib treatment should precede vaccine, to precondition the immune system, to maximize the response to vaccine-mediated immune enhancement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.